AU2002256085A1 - Quinoline inhibitors of hyak1 and hyak3 kinases - Google Patents

Quinoline inhibitors of hyak1 and hyak3 kinases

Info

Publication number
AU2002256085A1
AU2002256085A1 AU2002256085A AU2002256085A AU2002256085A1 AU 2002256085 A1 AU2002256085 A1 AU 2002256085A1 AU 2002256085 A AU2002256085 A AU 2002256085A AU 2002256085 A AU2002256085 A AU 2002256085A AU 2002256085 A1 AU2002256085 A1 AU 2002256085A1
Authority
AU
Australia
Prior art keywords
hyak1
hyak3
kinases
quinoline inhibitors
quinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002256085A
Other languages
English (en)
Inventor
Deborah L. Bryan
Joelle L. Burgess
James F. Callahan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU2002256085A1 publication Critical patent/AU2002256085A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
AU2002256085A 2001-04-06 2002-04-04 Quinoline inhibitors of hyak1 and hyak3 kinases Abandoned AU2002256085A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28222901P 2001-04-06 2001-04-06
US60/282,229 2001-04-06
PCT/US2002/010657 WO2002081728A2 (en) 2001-04-06 2002-04-04 Quinoline inhibitors of hyak1 and hyak3 kinases

Publications (1)

Publication Number Publication Date
AU2002256085A1 true AU2002256085A1 (en) 2002-10-21

Family

ID=23080586

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002256085A Abandoned AU2002256085A1 (en) 2001-04-06 2002-04-04 Quinoline inhibitors of hyak1 and hyak3 kinases

Country Status (5)

Country Link
US (1) US7087758B2 (enExample)
EP (1) EP1372654A4 (enExample)
JP (1) JP2004526756A (enExample)
AU (1) AU2002256085A1 (enExample)
WO (1) WO2002081728A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100453946B1 (ko) * 2002-10-11 2004-10-20 (주) 비엔씨바이오팜 6-메틸피리딘 유도체, 그 제조방법 및 이를 포함하는 항바이러스용 약학적 조성물
US7482455B2 (en) 2002-10-16 2009-01-27 Smithkline Beecham Corporation Chemical compounds
EP1718297A4 (en) * 2004-01-09 2009-09-02 Smithkline Beecham Corp NEW CHEMICAL COMPOUNDS
AR053602A1 (es) * 2005-05-03 2007-05-09 Smithkline Beecham Corp Compuesto de 2- arilamino -4-oxo-1,3-tiazol-5(4h)- substituido, composicion farmaceutica que lo comprende, proceso para prepararla y uso del compuesto para preparar un medicamento
PE20070083A1 (es) * 2005-06-08 2007-01-27 Smithkline Beecham Corp (5z)-5-(6-quinoxalinilmetilideno)-2-[(2,6-diclorofenil)amino]-1,3-tiazol-4(5h)-ona
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
US8106071B2 (en) * 2007-02-21 2012-01-31 Biobud Co., Ltd. Compositions for treating hyperproliferative vascular disorders and cancers
US20100286041A1 (en) * 2007-03-22 2010-11-11 Smithkline Beecham Corporation (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5h)-one
WO2009001224A2 (en) 2007-06-22 2008-12-31 Eth Zurich Antivirals
TWI504395B (zh) 2009-03-10 2015-10-21 Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
TW201038565A (en) 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
TWI475020B (zh) 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
TWI461197B (zh) 2009-03-12 2014-11-21 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
CA2809287C (en) 2010-08-27 2018-05-22 Gruenenthal Gmbh Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators
WO2012025237A1 (en) 2010-08-27 2012-03-01 Grünenthal GmbH Substituted 2-amino-quinoline-3-carboxamides as kcnq2/3 modulators
PT2609083E (pt) 2010-08-27 2015-07-01 Gruenenthal Gmbh 2-oxi-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3
EP2611780A1 (en) 2010-09-01 2013-07-10 Grünenthal GmbH Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as kcnq2/3 modulators
US12012394B2 (en) 2018-02-19 2024-06-18 Washington University Alpha-synuclein ligands
JP2025529185A (ja) * 2022-08-30 2025-09-04 パンネックス セラピューティクス インコーポレイテッド パネキシン－１調節剤及びパネキシン－１が関与する疾患の治療方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3210063A1 (de) * 1982-03-19 1983-09-22 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
PT79699B (en) * 1983-12-22 1986-12-10 Pfizer Process for preparing quinolone inotropic agents
GB8727737D0 (en) 1987-11-26 1987-12-31 Ici Plc Antitumour agents
WO1996028444A1 (en) 1995-03-15 1996-09-19 Pfizer Inc. 5,10-DIHYDROPYRIMIDO[4,5-b]QUINOLIN-4(1H)-ONE TYROSINE KINASE INHIBITORS
US6342514B1 (en) * 1996-10-23 2002-01-29 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US6225329B1 (en) 1998-03-12 2001-05-01 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
EP1147094A1 (en) * 1999-01-15 2001-10-24 Novo Nordisk A/S Non-peptide glp-1 agonists
JP2000309585A (ja) * 1999-02-26 2000-11-07 Kyorin Pharmaceut Co Ltd ６−置換ヘテロキノリンカルボン酸誘導体とその付加塩及びそれらの製造方法
GB0109103D0 (en) * 2001-04-11 2001-05-30 Pfizer Ltd Novel compounds

Also Published As

Publication number Publication date
WO2002081728A3 (en) 2002-11-21
WO2002081728A2 (en) 2002-10-17
EP1372654A2 (en) 2004-01-02
EP1372654A4 (en) 2007-10-03
US20050043352A1 (en) 2005-02-24
JP2004526756A (ja) 2004-09-02
US7087758B2 (en) 2006-08-08

Similar Documents

Publication Publication Date Title
AU2002213485A1 (en) Inhibitors of protein kinases
AU2002256085A1 (en) Quinoline inhibitors of hyak1 and hyak3 kinases
AU2001285163A1 (en) Quinoline inhibitors of cgmp phosphodiesterase
AU2002308748A1 (en) Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
AU2003303128A1 (en) Inhibitors and methods of use thereof
AU2002256418A1 (en) Inhibitors of bace
IL161921A0 (en) 3-Cyanoquinolines as inhibitors of egf-r and her2 kinases
AU2002314466A1 (en) Withasol and methods of use
AU6340600A (en) Telomerase inhibitors and methods of their use
AU2002338806A1 (en) Pharmaceutical combinations of pde-v inhibitors and other agents
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
AU2002306624A1 (en) Heterocyclic analgesic compounds and methods of use thereof
AU2003210983A1 (en) Kinase inhibitors and methods of use thereof
AU2002362935A1 (en) Kinases and phosphatases
AU2002303258A1 (en) Kinases and phosphatases
MXPA03009257A (es) Derivados de isoxaxol como inhibidores de src y otras proteinas cinasas.
AU2002338734A1 (en) Use of phosphorodiesterase IV inhibitors
AU2002306734A1 (en) Inhibitors of plasmepsins
AU2001232809A1 (en) Gyrase inhibitors and uses thereof
AU2001255696A1 (en) Telomerase inhibitors and methods of their use
AU2002363938A1 (en) Methods and use of motoneuronotropic factors
AU2002306845A1 (en) Telomerase inhibitors and methods of their use
AU2002360513A1 (en) Kinases and phosphatases
AU2002303878A1 (en) Kinases and phosphatases
AU2876000A (en) Tyrosine kinase inhibitors and methods of using the same

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase